【摘要】 目的　探讨急性白血病患者血清可溶性Fas配基 (sFasL )的水平及其临床意义。方法　采用酶联免疫吸附试验(ELISA)对 5 0例急性白血病患者的血清sFasL含量进行检测 ,比较不同病理状态急性白血病患者血清sFasL水平的变化。结果血清sFasL含量 :初治急性淋巴细胞白血病 (ALL)为 (0 .2 4± 0 .0 8)ng/ml ,急性髓性白血病 (AML )为 (0 .2 3± 0 .11)ng/ml;未缓解/复发组ALL为 (0 .2 3± 0 .0 9)ng/ml,AML为 (0 .2 1± 0 .0 8)ng/ml ;与完全缓解 /部分缓解组ALL的 (0 .15± 0 .0 6)ng/ml、AML的 (0 .15± 0 .0 5 )ng/ml及正常对照组的 (0 .13± 0 .0 5 )ng/ml相比 ,除AML未缓解 /复发与完全缓解 /部分缓解组相比无显著性差异 (P >0 .0 5 )外 ,其余均有非常显著性差异 (P <0 .0 1)。血清sFas水平与急性白血病未缓解或复发相关。结论　血清sFasL含量的测定可用于评估急性白血病的病理状态、化疗效果及预后更多还原

【Abstract】 Objective To study the clinical role and serum level of soluble Fas(Apo 1,CD95) ligand(sFasL) in patients with acute leukemia.Methods Serum levels of sFasL were measured by enzyme linked immunosorbent assay(ELISA) in 50 patients with acute leukemia.Results The serum sFasL levels were significantly higher in newly diagnosis or non remission/relapsed patients with acute lymphoblastic leukemia(ALL) or acute myeloid leukemia(AML) than those in completely/partial remission(CR/PR) (ALL or AML) group or control subjects ( ±s :0.24±0.08,0.23±0.11,0.23±0.09,0.21±0.08,0.15±0.06,0.15±0.05 and 0.13±0.05,respectively; P <0.01 in each comparison except in NR/relapsed versus CR/PR of AML( P >0.05).Moreover,the serum sFasL concentrations could be correlated with NR/relapsed acute leukemia.Conclusion Determination of serum sFasL might be a parameter associated with acute leukemia activity,and might be used in evaluation of treatment response and prognosis.更多还原